Focus Partners Wealth
ALLO icon

Focus Partners Wealth’s Allogene Therapeutics ALLO Stock Holding History

Focus Partners Wealth’s Portfolio ALLO Stock Details ALLO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$24.5K Sell
11,788
-7,468
-39% -$16.4K ﹤0.01% 2720
2026
Q1 		$47K Buy
+19,256
New +$38.6K ﹤0.01% 2584

Other funds holding ALLO

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
P
Pfizer New York $170M AUM 191.09% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $5B AUM 58.56% 1-Year Est. Return
SCM
Sio Capital Management New York $604M AUM 96.57% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Focus Partners Wealth's ALLO Position: Q2 2026 in Review

Focus Partners Wealth reduced its Allogene Therapeutics (ALLO) stake by 39% in Q2 2026, selling an estimated $16.4K and leaving 11,788 shares worth $24.5K. The position accounts for ﹤0.01% of the portfolio, ranked #2720.

Focus Partners Wealth first reported a position in ALLO in Q1 2026 and has held it in 2 quarters since. The position peaked at $47K in Q1 2026. 209 funds tracked by Wall St. Rank hold ALLO as of Q2 2026.

  • Focus Partners Wealth held 11,788 shares of Allogene Therapeutics worth $24.5K as of Q2 2026.
  • Focus Partners Wealth sold 7,468 Allogene Therapeutics shares in Q2 2026, an estimated $16.4K.
  • Allogene Therapeutics made up ﹤0.01% of Focus Partners Wealth's portfolio in Q2 2026, its #2720 holding.
  • Focus Partners Wealth first reported a position in Allogene Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • Focus Partners Wealth's Allogene Therapeutics position peaked at $47K in Q1 2026.
  • 209 funds tracked by Wall St. Rank held Allogene Therapeutics as of Q2 2026.

Based on Focus Partners Wealth's 13F filing for Q2 2026, filed 12 Aug 2026.